CC
AUTL

Cannell Capital’s Autolus Therapeutics AUTL Stock Holding History

Cannell Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,835
Closed -$31K – 69
2023
Q1 		$31K Hold
16,835
– – 0.01% 79
2022
Q4 		$32K Hold
16,835
– – 0.01% 80
2022
Q3 		$36K Buy
16,835
+12,834
+321% +$38K 0.01% 83
2022
Q2 		$11K Buy
+4,001
New +$12.2K ﹤0.01% 76

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Cannell Capital's AUTL Position: Q2 2023 in Review

Cannell Capital sold out of Autolus Therapeutics (AUTL) in Q2 2023, closing a stake of 16,835 shares — an estimated $31K sold.

Cannell Capital first reported a position in AUTL in Q2 2022 and held it in 4 quarters. The position peaked at $36K in Q3 2022. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2023.

  • Cannell Capital reported no remaining Autolus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 16,835 Autolus Therapeutics shares in Q2 2023, an estimated $31K.
  • Cannell Capital first reported a position in Autolus Therapeutics in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's Autolus Therapeutics position peaked at $36K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.